Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 4, Randomized, Open-label, Comparative, Multicenter Study to Assess the Safety and Efficacy of Induction Agents, Alemtuzumab, Basiliximab or Rabbit Anti-thymocyte Globulin in Combination With Tacrolimus, MMF, and a Rapid Steroid Withdrawal in Renal Transplant Recipients

NCT00113269 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT00113269
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00113269 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 4, Randomized, Open-label, Comparative, Multicenter Study to Assess the Safety and Efficacy of Induction Agents, Alemtuzumab, Basiliximab or Rabbit Anti-thymocyte Globulin in Combination With Tacrolimus, MMF, and a Rapid Steroid Withdrawal in Renal Transplant Recipients
Lead sponsor
Astellas Pharma Inc
Phase
Phase 4
Overall status
Completed
Start date
May 31, 2005
Completion date
March 31, 2009
Enrollment
501 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

kidney transplantation